Allan Michael Jordan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Allan Michael Jordan has a total of 466 co-authors. Here are the top co-authors by number of shared publications:
Donald Ogilvie
Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield, UK
16 shared publicationsIan Waddell
Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield, UK
13 shared publicationsDonald J. Ogilvie
Univ Manchester, Canc Res UK Manchester Inst, Drug Discovery Unit, Alderley Pk, Macclesfield SK10 4TG, Cheshire, England
11 shared publicationsIan D. Waddell
Univ Manchester, Canc Res UK Manchester Inst, Drug Discovery Unit, Alderley Pk, Macclesfield SK10 4TG, Cheshire, England
11 shared publicationsNicola Hamilton
University of Manchester Wilmslow Road
10 shared publicationsBohdan Waszkowycz
Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester , Wilmslow Road, Manchester, M20 4BX, United Kingdom
9 shared publications
Latest Publications
- 21 August 2026
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 37 (9) , 1798-1803
Beyond Cytotoxic Payloads for Antibody Drug Conjugates─A Medicinal Chemistry Perspective
Despite significant research and investment, antibody–drug conjugates (ADCs) primarily rely on a limited number of broadly cytotoxic payloads that contribute significantly to toxicity. More recently, there has been a migration toward mechanistically targeted payloads, pairing improved antibodies with small molecules that act on disease-specific biology, improving precision and tolerability. Designing these next-generation payloads means rethinking some of our design metrics and guidelines derived from traditional medicinal chemistry: properties such as LogD, pKa, permeability, efflux, and metabolic stability must be carefully balanced to ensure efficient intracellular release while limiting systemic exposure. Here we discuss our observations around these properties and suggest design rules and guidelines for the optimization of next-generation ADC payloads.
- 21 August 2026
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 37 (9) , 1798-1803
Beyond Cytotoxic Payloads for Antibody Drug Conjugates─A Medicinal Chemistry Perspective
Despite significant research and investment, antibody–drug conjugates (ADCs) primarily rely on a limited number of broadly cytotoxic payloads that contribute significantly to toxicity. More recently, there has been a migration toward mechanistically targeted payloads, pairing improved antibodies with small molecules that act on disease-specific biology, improving precision and tolerability. Designing these next-generation payloads means rethinking some of our design metrics and guidelines derived from traditional medicinal chemistry: properties such as LogD, pKa, permeability, efflux, and metabolic stability must be carefully balanced to ensure efficient intracellular release while limiting systemic exposure. Here we discuss our observations around these properties and suggest design rules and guidelines for the optimization of next-generation ADC payloads.
- Open Access
- 13 July 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (29) , 43300-43308
Combining Artificial Intelligence and Human Expertise in Pursuit of Novel PolQ Inhibitors
Application of generative AI, synergistically with traditional knowledge-based approaches, has expedited the discovery of small-molecule PolQ polymerase domain inhibitors. Leveraging AI-generated ligand designs, a structurally diverse set of compounds were synthesized and evaluated, ultimately identifying a novel oxime-based scaffold as a promising starting point. Although the initial hit demonstrated only modest biochemical potency, the oxime moiety─an unexplored vector in this chemical space─offered an opportunity for strategic substitution. Gratifyingly, using this strategy, a highly potent array of functionalized oxime PolQ inhibitors displaying promising initial ADME properties was delivered, underscoring the power of generative AI to unlock new chemical space and accelerate lead optimization.
- 13 July 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (29) , 43300-43308
Open AccessCombining Artificial Intelligence and Human Expertise in Pursuit of Novel PolQ Inhibitors
Application of generative AI, synergistically with traditional knowledge-based approaches, has expedited the discovery of small-molecule PolQ polymerase domain inhibitors. Leveraging AI-generated ligand designs, a structurally diverse set of compounds were synthesized and evaluated, ultimately identifying a novel oxime-based scaffold as a promising starting point. Although the initial hit demonstrated only modest biochemical potency, the oxime moiety─an unexplored vector in this chemical space─offered an opportunity for strategic substitution. Gratifyingly, using this strategy, a highly potent array of functionalized oxime PolQ inhibitors displaying promising initial ADME properties was delivered, underscoring the power of generative AI to unlock new chemical space and accelerate lead optimization.
- 19 September 2024
- Published by Elsevier
- Vol. 63 (1) , 61-160
To homeostasis and beyond! Recent advances in the medicinal chemistry of heterobifunctional derivatives
- 19 September 2024
- Published by Elsevier
- Vol. 63 (1) , 61-160
To homeostasis and beyond! Recent advances in the medicinal chemistry of heterobifunctional derivatives
- Open Access
Breaking Bad Proteins—Discovery Approaches and the Road to Clinic for Degraders
Proteolysis-targeting chimeras (PROTACs) describe compounds that bind to and induce degradation of a target by simultaneously binding to a ubiquitin ligase. More generally referred to as bifunctional degraders, PROTACs have led the way in the field of targeted protein degradation (TPD), with several compounds currently undergoing clinical testing. Alongside bifunctional degraders, single-moiety compounds, or molecular glue degraders (MGDs), are increasingly being considered as a viable approach for development of therapeutics, driven by advances in rational discovery approaches. This review focuses on drug discovery with respect to bifunctional and molecular glue degraders within the ubiquitin proteasome system, including analysis of mechanistic concepts and discovery approaches, with an overview of current clinical and pre-clinical degrader status in oncology, neurodegenerative and inflammatory disease.
Open AccessBreaking Bad Proteins—Discovery Approaches and the Road to Clinic for Degraders
Proteolysis-targeting chimeras (PROTACs) describe compounds that bind to and induce degradation of a target by simultaneously binding to a ubiquitin ligase. More generally referred to as bifunctional degraders, PROTACs have led the way in the field of targeted protein degradation (TPD), with several compounds currently undergoing clinical testing. Alongside bifunctional degraders, single-moiety compounds, or molecular glue degraders (MGDs), are increasingly being considered as a viable approach for development of therapeutics, driven by advances in rational discovery approaches. This review focuses on drug discovery with respect to bifunctional and molecular glue degraders within the ubiquitin proteasome system, including analysis of mechanistic concepts and discovery approaches, with an overview of current clinical and pre-clinical degrader status in oncology, neurodegenerative and inflammatory disease.
- Open Access
- 12 February 2024
- Published by MDPI AG in Preprints.org
Breaking Bad Proteins – Discovery Approaches and the Road to Clinic for Degraders
Proteolysis Targeting Chimeras (PROTACs) describe compounds that bind to and induce degradation of a target by simultaneously binding to a ubiquitin ligase. More generally referred to as bifunctional degraders, PROTACs have led the way in the field of targeted protein degradation (TPD) with several compounds currently undergoing clinical testing. Alongside bifunctional degraders, single-moiety compounds, or molecular glue degraders (MGDs), are increasingly being considered as a viable approach for development of therapeutics, driven by advances in rational discovery approaches. This review focusses on drug discovery with respect to bifunctional and molecular glue degraders within the ubiquitin proteasome system, including analysis of mechanistic concepts and discovery approaches, with an overview of current clinical and pre-clinical degrader status in oncology, neurodegenerative and inflammatory disease.
- 12 February 2024
- Published by MDPI AG in Preprints.org
Open AccessBreaking Bad Proteins – Discovery Approaches and the Road to Clinic for Degraders
Proteolysis Targeting Chimeras (PROTACs) describe compounds that bind to and induce degradation of a target by simultaneously binding to a ubiquitin ligase. More generally referred to as bifunctional degraders, PROTACs have led the way in the field of targeted protein degradation (TPD) with several compounds currently undergoing clinical testing. Alongside bifunctional degraders, single-moiety compounds, or molecular glue degraders (MGDs), are increasingly being considered as a viable approach for development of therapeutics, driven by advances in rational discovery approaches. This review focusses on drug discovery with respect to bifunctional and molecular glue degraders within the ubiquitin proteasome system, including analysis of mechanistic concepts and discovery approaches, with an overview of current clinical and pre-clinical degrader status in oncology, neurodegenerative and inflammatory disease.
- 3 February 2023
- Published by Royal Society of Chemistry (RSC)
- p. 40-93
Synthesis in Medicinal Chemistry
The discovery, optimisation and manufacture of medicines are processes underpinned by synthesis on scales from milligrams to tonnes; synthetic or semi-synthetic pharmaceuticals remain the cornerstones of modern medicines, as chemists innovate to deliver molecules to address contemporary challenges. This chapter reviews the crucial impact of synthesis, considering changing practices, contemporary developments in technology and methodology, and provides a view to how things may develop in future.
- 3 February 2023
- Published by Royal Society of Chemistry (RSC)
- p. 40-93
Synthesis in Medicinal Chemistry
The discovery, optimisation and manufacture of medicines are processes underpinned by synthesis on scales from milligrams to tonnes; synthetic or semi-synthetic pharmaceuticals remain the cornerstones of modern medicines, as chemists innovate to deliver molecules to address contemporary challenges. This chapter reviews the crucial impact of synthesis, considering changing practices, contemporary developments in technology and methodology, and provides a view to how things may develop in future.
- Top Cited Papers
- 27 September 2021
- Published by Springer Nature in Nature Cancer
- Vol. 2 (10) , 1002-1017
Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia
- 27 September 2021
- Published by Springer Nature in Nature Cancer
- Vol. 2 (10) , 1002-1017
Top Cited PapersDiscovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia
- Open Access
- 26 May 2021
- Published by Springer Nature in British Journal of Cancer
- Vol. 125 (4) , 473-478
Molecularly profiled trials: toward a framework of actions for the “nil actionables”
The sequencing of tumour or blood samples is increasingly used to stratify patients into clinical trials of molecularly targeted agents, and this approach has frequently demonstrated clinical benefit for those who are deemed eligible. But what of those who have no clear and evident molecular driver? What of those deemed to have “nil actionable” mutations? How might we deliver better therapeutic opportunities for those left behind in the clamour toward stratified therapeutics? And what significant learnings lie hidden in the data we amass but do not interrogate and understand? This Perspective article suggests a holistic approach to the future treatment of such patients, and sets a framework through which significant additional patient benefit might be achieved. In order to deliver upon this framework, it encourages and invites the clinical community to engage more enthusiastically and share learnings with colleagues in the early drug discovery community, in order to deliver a step change in patient care.
- 26 May 2021
- Published by Springer Nature in British Journal of Cancer
- Vol. 125 (4) , 473-478
Open AccessMolecularly profiled trials: toward a framework of actions for the “nil actionables”
The sequencing of tumour or blood samples is increasingly used to stratify patients into clinical trials of molecularly targeted agents, and this approach has frequently demonstrated clinical benefit for those who are deemed eligible. But what of those who have no clear and evident molecular driver? What of those deemed to have “nil actionable” mutations? How might we deliver better therapeutic opportunities for those left behind in the clamour toward stratified therapeutics? And what significant learnings lie hidden in the data we amass but do not interrogate and understand? This Perspective article suggests a holistic approach to the future treatment of such patients, and sets a framework through which significant additional patient benefit might be achieved. In order to deliver upon this framework, it encourages and invites the clinical community to engage more enthusiastically and share learnings with colleagues in the early drug discovery community, in order to deliver a step change in patient care.
- Open Access
Glucose 6-Phosphate Dehydrogenase from Trypanosomes: Selectivity for Steroids and Chemical Validation in Bloodstream Trypanosoma brucei
Glucose 6-phosphate dehydrogenase (G6PDH) fulfills an essential role in cell physiology by catalyzing the production of NADPH+ and of a precursor for the de novo synthesis of ribose 5-phosphate. In trypanosomatids, G6PDH is essential for in vitro proliferation, antioxidant defense and, thereby, drug resistance mechanisms. So far, 16α-brominated epiandrosterone represents the most potent hit targeting trypanosomal G6PDH. Here, we extended the investigations on this important drug target and its inhibition by using a small subset of androstane derivatives. In Trypanosoma cruzi, immunofluorescence revealed a cytoplasmic distribution of G6PDH and the absence of signal in major organelles. Cytochemical assays confirmed parasitic G6PDH as the molecular target of epiandrosterone. Structure-activity analysis for a set of new (dehydro)epiandrosterone derivatives revealed that bromination at position 16α of the cyclopentane moiety yielded more potent T. cruzi G6PDH inhibitors than the corresponding β-substituted analogues. For the 16α brominated compounds, the inclusion of an acetoxy group at position 3 either proved detrimental or enhanced the activity of the epiandrosterone or the dehydroepiandrosterone derivatives, respectively. Most derivatives presented single digit μM EC50 against infective T. brucei and the killing mechanism involved an early thiol-redox unbalance. This data suggests that infective African trypanosomes lack efficient NADPH+-synthesizing pathways, beyond the Pentose Phosphate, to maintain thiol-redox homeostasis.
Open AccessGlucose 6-Phosphate Dehydrogenase from Trypanosomes: Selectivity for Steroids and Chemical Validation in Bloodstream Trypanosoma brucei
Glucose 6-phosphate dehydrogenase (G6PDH) fulfills an essential role in cell physiology by catalyzing the production of NADPH+ and of a precursor for the de novo synthesis of ribose 5-phosphate. In trypanosomatids, G6PDH is essential for in vitro proliferation, antioxidant defense and, thereby, drug resistance mechanisms. So far, 16α-brominated epiandrosterone represents the most potent hit targeting trypanosomal G6PDH. Here, we extended the investigations on this important drug target and its inhibition by using a small subset of androstane derivatives. In Trypanosoma cruzi, immunofluorescence revealed a cytoplasmic distribution of G6PDH and the absence of signal in major organelles. Cytochemical assays confirmed parasitic G6PDH as the molecular target of epiandrosterone. Structure-activity analysis for a set of new (dehydro)epiandrosterone derivatives revealed that bromination at position 16α of the cyclopentane moiety yielded more potent T. cruzi G6PDH inhibitors than the corresponding β-substituted analogues. For the 16α brominated compounds, the inclusion of an acetoxy group at position 3 either proved detrimental or enhanced the activity of the epiandrosterone or the dehydroepiandrosterone derivatives, respectively. Most derivatives presented single digit μM EC50 against infective T. brucei and the killing mechanism involved an early thiol-redox unbalance. This data suggests that infective African trypanosomes lack efficient NADPH+-synthesizing pathways, beyond the Pentose Phosphate, to maintain thiol-redox homeostasis.
- Open Access
- 28 February 2020
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 11 (4) , 497-505
Discovery and Optimization of wt-RET/KDR-Selective Inhibitors of RETV804M Kinase
A combination of focused library and virtual screening, hit expansion, and rational design has resulted in the development of a series of inhibitors of RETV804M kinase, the anticipated drug-resistant mutant of RET kinase. These agents do not inhibit the wild type (wt) isoforms of RET or KDR and therefore offer a potential adjunct to RET inhibitors currently undergoing clinical evaluation.
- 28 February 2020
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 11 (4) , 497-505
Open AccessDiscovery and Optimization of wt-RET/KDR-Selective Inhibitors of RETV804M Kinase
A combination of focused library and virtual screening, hit expansion, and rational design has resulted in the development of a series of inhibitors of RETV804M kinase, the anticipated drug-resistant mutant of RET kinase. These agents do not inhibit the wild type (wt) isoforms of RET or KDR and therefore offer a potential adjunct to RET inhibitors currently undergoing clinical evaluation.